NCT01747980View on ClinicalTrials.gov

Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

March 31, 2014

Conditions
Gaucher Disease
Interventions
DRUG

PRX-112

Single dose level, four doses per cohort

Trial Locations (2)

31096

Rambam Medical Center, Haifa

91031

Shaare Zedek Medical Center, Jerusalem

All Listed Sponsors
lead

Protalix

INDUSTRY

NCT01747980 - Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients | Biotech Hunter | Biotech Hunter